Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Phase 1 Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

Solid Tumors

Ongoing, but not recruiting

1

Start Date 09/01/2008

Age of Trial (yrs) 16.2

Gleevec-resistant

KIT/PDGFRA inhibitor + IGF1R inhibitor

Block KIT + Block related tumor signal paths

GIST not specified. GIST patient enrollment unknown.

A4021024

Pfizer

EmergingMed (877) 369-9753 PfizerCancerTrials@emergingmed.com Pfizer CT.gov Call Center 1-800-718-1021

Oral IV

This phase I trial combines a potent KIT inhibitor (Sutent) with an IGF-1R inhibitor. This combination might be especially appropriate for wild-type GIST since Sutent is a potent inhibitor of wild-type KIT and since IGF-1R is overexpressed in wild-type GISTs. Patients with pediatric type GIST but who are over the age of 18 would also be good candidates for this trial.
Both drugs are made by Pfizer.
Patients must be over 18 years old.